Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD

By LabMedica International staff writers
Posted on 26 Jul 2026

Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide. More...

A new collaboration now targets development of high‑throughput diagnostics that integrate sputum‑based cellular and proteomic readouts to guide more personalized treatment decisions.

bioAffinity Technologies (San Antonio, TX, USA) and Pictor (Carlsbad, CA, USA) have partnered to develop and commercialize next‑generation diagnostics intended to give clinicians a more complete picture of lung inflammation in asthma and chronic obstructive pulmonary disease. The collaboration combines bioAffinity’s expertise in flow cytometry with Pictor’s targeted proteomic analysis platform to characterize immune cell populations and cytokine patterns associated with airway inflammation. 

The tests are designed to help match patients to more effective treatments based on their specific inflammatory profile. The work builds on bioAffinity’s proprietary sputum analysis platform that also underpins CyPath Lung, a noninvasive test used to assess the likelihood that a pulmonary nodule is malignant.

The approach integrates multiparameter flow cytometry to differentiate and quantify sputum immune cell subsets with rapid, focused cytokine profiling to capture key inflammatory signals produced by those cells. By unifying these data streams, the partners aim to deliver a laboratory‑friendly workflow that increases throughput, reduces testing complexity, and lowers costs compared with traditional single‑analyte methods. 

The anticipated outcome is a test that supports more informed decisions when considering advanced therapies, including U.S. Food and Drug Administration (FDA)‑approved biologics and emerging targeted treatments. The tests under development are anticipated to be initially offered as Laboratory Developed Tests (LDTs) under the Clinical Laboratory Improvement Amendments (CLIA). 

bioAffinity has multiple patents pending related to its asthma and chronic obstructive pulmonary disease testing platform and will own intellectual property arising from the collaboration, while Pictor will retain ownership of its existing targeted proteomic platform intellectual property and new inventions related to it.

“Asthma and COPD are not single diseases. They encompass multiple inflammatory pathways that require different therapeutic approaches. By measuring immune cell populations using flow cytometry and integrating Pictor’s cytokine profiling platform into its test protocol, our new diagnostics are designed to advance precision medicine in asthma and COPD by providing physicians with a more complete understanding of the biological processes driving airway inflammation in real time,” said Gordon Downie, MD, PhD, bioAffinity’s Chief Medical Officer.

“We're excited to partner with bioAffinity Technologies as they continue to develop innovative, non-invasive tests for lung disease. By combining bioAffinity's expertise in immune cell biology with Pictor's scalable proteomic platform, we can advance bioAffinity’s ability to provide insights that move beyond simply identifying disease to understanding the underlying biology of each patient’s condition, leading to more effective treatments,” said Dr. Jamie Platt, CEO of Pictor.

Related Links
bioAffinity Technologies
Pictor


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.